IMNM (STOCKS)
Immunome, Inc.
$22.680000
+1.010000 (+4.66%)
Prev close: $21.670000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Clay B. Siegall
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,556.81M
- Employees
- 155
- P/E (TTM)
- -9.32
- P/B (TTM)
- 3.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
13
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.76 | $-0.61 | -0.1460 | -23.78% |
|
Sep 2025 (Q3)
|
$-0.65 | $-0.59 | -0.0643 | -10.98% |
|
Jun 2025 (Q2)
|
$-0.50 | $-0.54 | +0.0395 | +7.32% |
|
Mar 2025 (Q1)
|
$-0.52 | $-0.69 | +0.1747 | +25.15% |
Financial Statements
| Revenues | $6.94M |
| Benefits Costs and Expenses | $219.34M |
| Costs And Expenses | $219.34M |
| Operating Expenses | $231.05M |
| Research and Development | $177.29M |
| Other Operating Expenses | $53.77M |
| Operating Income/Loss | -$224.11M |
| Income/Loss From Continuing Operations After Tax | -$212.39M |
| Income/Loss From Continuing Operations Before Tax | -$212.39M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Income/Expense After Provision For Losses | $11.72M |
| Interest Income/Expense Operating, Net | $11.72M |
| Net Income/Loss | -$212.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$212.39M |
| Net Income/Loss Available To Common Stockholders, Basic | -$212.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$2.43 |
| Diluted Earnings Per Share | -$2.43 |
| Basic Average Shares | 87,350,956 |
| Diluted Average Shares | 87,350,956 |
| Assets | $683.19M |
| Current Assets | $660.78M |
| Noncurrent Assets | $22.41M |
| Fixed Assets | $14.64M |
| Other Non-current Assets | $7.78M |
| Liabilities | $48.85M |
| Current Liabilities | $44.99M |
| Accounts Payable | $3.34M |
| Wages | $11.53M |
| Other Current Liabilities | $30.12M |
| Noncurrent Liabilities | $3.86M |
| Equity | $634.34M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $634.34M |
| Liabilities And Equity | $683.19M |
| Net Cash Flow From Operating Activities | -$190.92M |
| Net Cash Flow From Operating Activities, Continuing | -$190.92M |
| Net Cash Flow From Investing Activities | $60.80M |
| Net Cash Flow From Investing Activities, Continuing | $60.80M |
| Net Cash Flow From Financing Activities | $640.36M |
| Net Cash Flow From Financing Activities, Continuing | $640.36M |
| Net Cash Flow | $510.24M |
| Net Cash Flow, Continuing | $510.24M |
| Comprehensive Income/Loss | -$212.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$212.45M |
| Other Comprehensive Income/Loss | -$57.00K |